Soraya is a board-certified MD graduated from Paris University specialized in Clinical Pharmacology and Biostatistics with 20 years of experience in Drug Development. She started her career in the academia before joining the industry with Orphan Europe, in the rare disease space. She then joined Sanofi for 9 years where she held increasing leadership positions within global R&D, leading gene therapy programs in cardiovascular and Ophthalmology. She took over the leadership of the Ophthalmology Division in 2012 and in this capacity, drove Sanofi strategy towards ocular gene therapy efforts while setting up a multidisciplinary R&D and business organization. Before joining Gyroscope mid-2017, Soraya served as SVP CMO at Lysogene, a biotech developing gene therapy treatment for rare CNS disorders. As a member of the executive team, she contributed to the successful listing of Lysogene on the European Stock Exchange Euronext.
At Gyroscope, Soraya serves as CEO and CMO driving the company s strategy and operations in developing gene therapies for the treatment of eye diseases linked to an unbalanced Complement System.
Chris is the Chief Investment Officer and a Managing Partner of Syncona Investment Management Ltd. Chris is a member of the boards of 3 Syncona Portfolio companies, NightstaRx Limited, Freeline Therapeutics Limited and Gyroscope Therapeutics Limited. Previously, he was a partner of Apposite Capital LLP, a venture and growth capital company focused on the healthcare and life science sector. During his time at Apposite, he was involved in a number of investments, which included Ambit Biosciences (acquired by Daiichi Sankyo), Convergence Pharmaceuticals (acquired by Biogen-Idec), Birdrock and the acquisition of a portfolio of nine US healthcare companies which included Zonare Medical Systems (acquired by Mindray) and Ulthera (acquired by Merz). Before Apposite, Chris had roles with Bioscience Managers Ltd, Neptune Investment Management Ltd and as a medicinal chemist in the pharmaceutical industry. Chris holds a degree in Natural Sciences and a PhD in Organic Chemistry, both from Cambridge University.
Iain joined Cambridge Enterprise in 2003. He manages the Life Science team that has a strong track record of spin out formation and licensing with a significant portfolio including alemtuzumab (Lemtrada) and spin-outs Mission Therapeutics, Cambridge Epigenetix, XO1 Therapeutics (sold to Janssen Pharmaceuticals), Z-factor and Phoremost. He led the Cambridge–GSK open innovation drug discovery initiative based at the SBC and was the Cambridge lead for the Apollo Therapeutics Fund.
David Kavanagh is the Professor of Complement Therapeutics at the National Renal Complement Therapeutics Centre (NRCTC). The NRCTC is a combined clinical, diagnostic and treatment centre for the complement mediated diseases: atypical haemolytic uraemic syndrome (aHUS) and C3 glomerulopathy. All patients in England treated with eculizumab for these diseases are managed through the NRCTC. His University research group has been at the forefront of defining the role of complement in renal disease and is fully integrated with the NRCTC to provide rapid translational benefits to patients. David moved to Newcastle to start his own lab in 2008 with a Wellcome Trust Fellowship following a Kidney Research UK Fellowship at the University of Edinburgh. He was previously a Fellow at Washington University School of Medicine, St. Louis. He graduated in Medicine and Immunology from the University of Glasgow in 1998 and obtained his PhD from Newcastle University in 2006. For his work defining the role of complement in aHUS, he was awarded the Renal Association’s Young Investigator (Raine) award. Additionally, he runs a glomerulonephritis and vasculitis clinic at Freeman hospital. He is chairman of the aHUS rare disease working group, an executive committee member of Complement UK.
Anne has 25 years of experience in drug development across several therapeutic areas, in the last ten years with focus on rare diseases and specifically on gene therapy of the diseases. Most recently Anne was VP of Clinical Research Hematology and Global TA head of Hematology in Baxalta and in this role secured several new product approvals (US and EU). Prior to this Anne held various senior leadership positions at Novo Nordisk leading global drug development programs from research to commercialisation and bringing several products to market. Anne is a Medical Doctor from Copenhagen University and holds a PhD in Epidemiology. Anne was previously Board member of the Novo Nordisk Hemophilia Foundation.
AMD is the leading cause of irreversible blindness in the elderly and today there is no effective treatment for the atrophic form of the diseaseView More +
Gyroscope Therapeutics Ltd is developing cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement systemView More +
Gyroscope was founded to explore the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD) and gene therapy as a mode of treatment delivery.View More +